Epizyme Inc (NASDAQ:EPZM) has been given a consensus recommendation of “Buy” by the fifteen research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and twelve have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $23.00.
Several equities research analysts have issued reports on EPZM shares. ValuEngine cut shares of Epizyme from a “hold” rating to a “sell” rating in a research note on Monday, November 6th. Zacks Investment Research cut shares of Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Leerink Swann reaffirmed an “outperform” rating and set a $22.00 price target (down from $28.00) on shares of Epizyme in a research note on Thursday, November 2nd. BidaskClub raised shares of Epizyme from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 5th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $25.00 price target on shares of Epizyme in a research note on Wednesday, January 24th.
Epizyme (NASDAQ:EPZM) traded down $0.50 during trading on Wednesday, hitting $18.15. 300,850 shares of the company’s stock traded hands, compared to its average volume of 504,007. Epizyme has a one year low of $9.30 and a one year high of $20.45. The firm has a market cap of $1,220.00, a PE ratio of -8.00 and a beta of 2.19.
In other news, COO Matthew Ros sold 72,264 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the transaction, the chief operating officer now directly owns 74,867 shares in the company, valued at approximately $1,245,038.21. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 25.20% of the company’s stock.
Several hedge funds have recently made changes to their positions in EPZM. Teacher Retirement System of Texas purchased a new position in shares of Epizyme during the 4th quarter worth about $202,000. Tudor Investment Corp ET AL purchased a new position in shares of Epizyme during the 2nd quarter worth about $215,000. Fox Run Management L.L.C. purchased a new position in shares of Epizyme during the 3rd quarter worth about $223,000. Bailard Inc. purchased a new position in shares of Epizyme during the 4th quarter worth about $251,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Epizyme during the 4th quarter worth about $263,000. Institutional investors and hedge funds own 85.99% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Epizyme Inc (EPZM) Receives $23.00 Average PT from Analysts” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/17/epizyme-inc-epzm-receives-23-00-average-pt-from-analysts.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.